Skip to main content
Premium Trial:

Request an Annual Quote

Novacyt Raises $3.8M in Private Equity

NEW YORK (GenomeWeb) – Novacyt today announced it has raised 3.1 million ($3.8 million) in a private equity placement.

Institutional investor Alto Invest joined existing investors in the funding round.

"The fundraising will enable the company to significantly accelerate the commercialization of the world-class cytology platform, NovaPrep," Novacyt CEO Graham Mullis said in a statement. "In particular, it enables the company to expand its global commercial channels, including launching in key new markets in the next few months."

The firm said in a statement that it will use the funds to build sales in China and other new markets in Asia, as well as develop molecular diagnostics for infectious disease, beginning with new products targeting fungal infections including Aspergillus and Pneumocystis.

In May, Paris-based Novacyt bought diagnostic products and services firm Lab21 for $34.1 million.


The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.